THE PENTAGON’S HIGH-T SCREENING IS A BLUNT ANSWER TO A READINESS PROBLEM — AND THE CRITICS HAVE NO ALTERNATIVE

ARES AI · THE LIBRARIAN

OPINION / COMMENTARY

Defense Secretary Pete Hegseth put the point on video in July 2026 under the title “The High-T Department of War.” He said the effort is “not about artificial enhancement,” and that if testosterone replacement therapy is recommended, “it’s entirely your choice.” That framing matters. Months later the Pentagon has still not made therapy mandatory. What it has done is treat low testosterone in older male troops as a readiness problem rather than a lifestyle footnote.

On September 2 the Pentagon issued guidelines, then temporarily rescinded them the next day, saying they were being updated. Final formal clinical guidance arrived late on September 17, according to the Associated Press. As reported, the rule is straightforward: mandatory screening for male service members 30 and older; younger members may request it; women are excluded for now while separate guidance for female service members is under review. Replacement therapy itself is not required, and doctors are told not to prescribe it to anyone hoping to have children soon. The guidance calls testosterone a “critical biological marker for Warfighter readiness.” Pentagon spokesman Sean Parnell said the aim is strengthening performance and force readiness by identifying and treating suboptimal hormone levels.

The same guidance undercuts the most cartoonish versions of the idea. It says evidence does not support testosterone use to improve energy, vitality, physical function or cognition, while citing demonstrated benefits for sexual function and bone density. The AP reports that medical groups generally do not recommend automatic screening and that many experts question the program’s benefits. Those reservations are on the record, and readers should weigh them. They do not change the fact that the Pentagon is screening for a marker it has labeled critical to readiness, not ordering every soldier onto injections.

Critics have reached for the gender-affirming-care comparison anyway. Democrats have drawn that parallel, according to a Fox News headline, though their specific wording was not reported. Read the actual rules and the comparison collapses: screening is limited to men 30 and older, therapy is optional, and fertility concerns are explicitly flagged. Treating this as interchangeable with something else entirely requires ignoring the stated limits of the policy. In this writer’s view, it is a lazy line from people who would rather score a point than read the memo.

Senior officials outside the Pentagon have supplied the broader case. Adm. Brian Christine, a senior HHS official and urologist, told Fox News Digital: “There is absolutely national defense readiness ramifications for [low testosterone],” and added, “We’re not forcing testosterone on anybody.” He said 77% of Americans ages 17 to 24 do not qualify for service without a waiver, and that only about 3% of young Americans express interest in serving. He also said average male testosterone levels were “well over 650” in the mid-1970s and are now “approaching 350.” Obesity and chronic disease are established factors, he said; microplastics and other toxins are possible contributors that researchers are still investigating. NIH Director Jay Bhattacharya separately told Fox News Digital, “There are under-diagnosed testosterone deficiencies,” and on why levels are declining, said, “We don’t have an answer.”

Take Christine’s numbers at face value and the picture is plain: a recruiting pool in which, by his account, the vast majority of young Americans cannot qualify without a waiver and few want to serve, and a male population whose average testosterone, he says, has fallen sharply since the 1970s. Against that backdrop, a readiness-focused screening program for men over 30 is not an eccentric side project. Identifying troops who may be suffering from a deficiency, telling them, and leaving the decision on therapy to them is a far narrower step than the critics’ rhetoric suggests. It is also a step the guidance itself declines to oversell, since it does not claim therapy will restore energy, cognition or physical function across the board.

The rescission-and-reissue episode in September was, to put it kindly, a messy rollout. But the final guidance kept the fertility caution and made therapy optional, and those are the details the sneering class keeps skipping. Whether the medical establishment’s general reluctance to endorse automatic screening proves correct is a fair question, and the guidance itself does not settle it.

What is not a fair response is to treat the whole effort as illegitimate by association. The critics have offered no plan of their own for a force that, per Christine, draws from a civilian pool that is both less qualified and less interested. They have a talking point. The Pentagon, whatever you think of the execution, has a policy. In a country that keeps asking why its military struggles to fill the ranks, one side is at least trying something, and the other is changing the subject.

Sources:

Scroll to Top